Appendix 4C - quarterly* or having a go at doing so, page-30. ASX - By Stock. Report Created with Sketch. . For IXC I see the risk in one indication, comparatively lower TAM than others and different formulation for a week duration while phase II used daily. , page-4. Plus, the opportunity to explore other conditions, including hydrocephalus and meningitis. Global Phase 3 Trial of Presendin to Launch in Q4 2021Invex receives IND approvalInvex Receives Written Response from FDA on Type C Meeting, page-2. ASX - Day TradingInitial FDA and EMA Advice on Presendin Development, page-2. Invex Receives Approval for Paediatric Plan from the EMA, page-3. , page-3. , page-75. , page-5. Latest Posts Forums iShares Global Energy ETF (IXC) Add to watchlist NYSEArca - Nasdaq Real Time Price. @FullMoonFever Another chart request if you are up for it please thanks in advance, page-4. Advertise on HotCopper. Daily bounced well off support and now slowly creeping upId like to see a range develop now between say 18 - 23 before next bit of news, page-517. Charts. ASX - Short Term Trading. Of course IXC isnt the stock market but its coincidental that selling has stopped around this 17 cents mark which aligns with the old trend line from back in the days. . 3. IXC could also be worth $14 on a successful trial and licensing deal (or takeover). 0. If IXC is positioning itself as a takeover target and the trial endpoints allow for it, it would make sense to provide early readouts. ASX - By Stock. , page-2. Australia's largest stock trading and investment forum Australia's #1 stock forumInvex Successfully Concludes Protocol Assistance with EMA, page-2. Join the HotCopper ASX share market forum today for free. International Markets. 2 Upvote. Interexchange Carrier, also known as IXC, is a telco that mainly provides long-distance communication services. 4. ASX - Day Trading. Latest Posts ForumsHalf Yearly Report and AccountsWith debt too expensive and lots of very discounted capital raisings especially in the microcap part of the market, I'd like to think that IXC can take advantage of the fact that they have cash. . The Phase III raise encompassed the costs for a go-it-alone reformulation strategy, with Bell Potter suggesting in a Q&A with IXC that they saved $5-6M in going with Peptron for their reformulation supply/manufacturing, alongside 12 months in time. AX stock on Yahoo Finance. Australia's largest stock trading and investment forum Australia's #1 stock forum Australia's #1 stock forumUK R&D Tax Rebate. Plans & Pricing. Currency in USD 38. Access the latest research articles and market investment insight for INVEX THERAPEUTICS LTD seamlessly. . 8,369 likes · 140 talking about this · 1,407 were here. Last research or update on this I listened to was by FiftyOneCapital. Management ticking boxes while shareholders continue to have a golden opportunity to invest near all time lows in a company that has continually de-risked the fundamentals thesis. Market . We are supported by a Board of Advice which is made up of the premier leaders in the various fields in which we, Private Capital Advisers, specialise. ASX - By Stock. ASX - Day Tradingis invex releasing 2. Only took that large seller to sell, now liquidity has dried up and. Last updated 15. Latest Posts. Created with Sketch. . GW Ixc once again showing why you are the best mgmt team on the ASX . 64440. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of. pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. Invex to Present at Upcoming Tech Biotech Broker BriefingCreated with Sketch. 5mill options have been issued at a strike price of $1 First lot 250k to a soph. This is a complete waste of time and posting space - give yourself a break man and forget about trying to predict what is completely un-predictable. Notice of Investor Call and Presentation, page-3. Very impressive. . Latest Posts. But the market volume was very low, which points to a lack of interest, the long horizons of biotech, lack of publicising or Notification of cessation of securities - IXC. ASX - By Stock. . ASX - By Stock. 59). 0¢ Sentiment: Buy Disclosure: Held. These are 2007 numbers. ASX - Short Term Trading. I think having this out we can discuss on the way. ASX - Short Term Trading. AX stock on Yahoo Finance. View daily, weekly or monthly formats back to when Invex Therapeutics Ltd stock was issued. . A new thread to put trading comments / reasoning / opinions in. Appreciate your input Dr T. Charts. ASX - Day TradingCreated with Sketch. ASX - Day TradingCreated with Sketch. 147,415. I guess that&amp;apos;s why retail performs so poorly on average, so many think they are long term investors but can&amp;apos;t hold onto their shares for more. , page-6. . 0% $ODM 35. @FullMoonFever Another chart request if you are up for it please thanks in advance, page-8. . Created with Sketch. , page-3. Results of MeetingInvex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. Created with Sketch. , page-3. The announcement was certainly a setback but we're not dead in. ASX - Day TradingWith debt too expensive and lots of very discounted capital raisings especially in the microcap part of the market, I'd like to think that IXC can take advantage of the fact that they have cash. The company can always acquire something new or do some capital returns. Issue of Tranche 1 Placement Shares and Appendix 2A. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical developmentCreated with Sketch. 54am 24/11/2023 ? HotCopper has news, discussion, prices and market data on INCA MINERALS LIMITED. Created with Sketch. IXC needs to be proactive and release a statement. Maybe more common that what people think, imagine once GPs start diagnosing it even better if a treatment is developed, Prevalence could increase 2 or times which ultimately increases. Mernova, a subsidiary of Melodiol Global Health (ASX:ME1), is on track to achieve its highest ever monthly sales, with revenues expected to reach A$891,944 in October 2023. Created with Sketch. Created with Sketch. Hi Hot Copper, this will be a master thread for my daily posting of the Pharma Market Watchlist, please only keep commentary to the watchlist. Forums. Discover historical prices for IXC. ASX - By Stock. Market . Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. ASX - Day Trading. I find this very intriguing and positive that in last few weeks about 1. ASX - By Stock. Created with Sketch. rights. , page-3. Forums. @FullMoonFever Another chart request if you are up for it please thanks in advance, page-2. The fact it recovered and closed about the 1. . Forums. Results are our big catalyst Other catalysts include: - new indication - directors buying - half way through trial (120 patients recruited)At the request of a few posters who want to start afresh, welcome to the IXC charting thread going forward!If you're a poster who is inclined to track TA,. ASX - By Stock. here (arrow) per the NEU chart Close now to breaking trend and establishing a more upper trend into results IMO IXC Price at posting: 40. . Forums. 26 area could be wrong and it could go for example to $3. is there any news release, or SP increasing due to only the market showing interestInvex Receives UK Approval to Commence Phase III TrialInvex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. 6million shares?, and if so is anyone worried about this, release date 29th. Trading HaltIXC Valuation Report MST. 05. Market . My understanding is that NEU went from around $1. 5 cents. Expand. 1950. IXC Price at posting: 38. . ASX - Day TradingI sold around half my shares yesterday at 25c. *Close price adjusted for splits. What would you like to pay the world leader in IIH science as CSO, and how much of that salary you would expect to be spent on market to buy shares? Hi All, Having scrolled through the IXC forum for 18-24 months now, I have seen quite literally 200+ posts of charts discussing the stock price, and only a handful of posts discussing the fundamental analysis of the business itself, Publication of Invex IIH Phase II Pressure Trial Results. com. 7% #asx #ausbiz 23 Jun 2023 06:06:11Not been following IXC but it seems that this Orphan Drug Designation for TBI now have $0 value due to the other Phase III trial update and the company is. ASX - Short Term Trading. . IXC Valuation Report MST. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of. IXC Price at posting: 23. Created with Sketch. 3¢. $100-200k might be the minimum for the market to take notice. Created with Sketch. ASX - By Stock. ASX - By Stock. ASX - Short Term Trading. RDN Raiden Resources secures complete control of lithium at Arrow Project, buys out Arrow Minerals Ltd. . Created with Sketch. Good fundamental research starting points for IXC:Summary: IXC FactsheetMST Analyst Equity Research ReportFiftyOne Capital ReportPresentation - Tom Duthy. Contrast that to data from Wales in 2017 which suggests that. Invex Therapeutics Limited (ASX:IXC) is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. At the request of a few posters who want to start afresh, welcome to the IXC charting thread going forward!If you're a poster who is inclined to track TA,. is there any news release, or SP increasing due to only the market showing interestCreated with Sketch. ASX - Day TradingIf anyone told me a year ago, "there is a chance IXC cant progress the trial and the management all get sacked" I would agree that there was a chance, but nullified to a 1-2% black swan and worth the upside return profile. Very tempted to buy them back today at 19c. Hopefully they hit the miracle, at least I get something back from this if it goes balls up which in the bio world at the moment is highly likely. ASX - Day Trading0. ASX - Day TradingInvex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. Spot on - filled the 1. ASX - By Stock. Created with Sketch. View daily, weekly or monthly formats back to when Invex Therapeutics Ltd stock was issued. ASX - General. It was well aware of the claims made, released such information in the prospectus (and still had a hugely successful IPO), and would have done their due diligence before entering into any agreements with the University. 59 before first real pull back (those lines will be used in the future, they always set it up for that reason, being $3. Bumping up this thread as $3. IXC current EV is close to $0 so again Im not sure what OSL valuation is but I dont think it stacks up as good as IXC and where IXC is at in its timeline. Latest Posts. you post every single trade that is a sell onto Hotcopper. 19 Per share (Personal Estimate) vs MST Research report of $3. That is fair and as I mentioned in my initial post when buying, the business is worth the cash in ST. 392 10/12/19 20:43 Post #: 41898691 Share @FullMoonFever Another chart request if you are up for it please thanks in advance IXC Valuation Report MST. **Close price adjusted for splits and dividend and/or capital gain distributions. ASX - Day TradingI bought some today at 44. 1 Upvote. Top 20 remains holding 58% compared to 58. 0. . Date of AGM and Closing Date for Director NominationsCD is on the money once again, page-195. Trading HaltIXC Valuation Report MST. This is fantastic news and I appreciate the fact that it has not been heavily hyped by the company, makes you wonder what else is being worked on. Share Not unexpected. IXC Valuation Report MST. 333334. Created with Sketch. 1. STN Saturn Metals reports high-grade gold intersections and visible gold at Apollo Hill, WAInvex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. IXC Valuation Report MST. ASX - By Stock. Just a matter of time really. Invex Therapeutics Ltd. ASX - General. IXC Valuation Report MST. Created with Sketch. . Some people like to gamble on stocks, others invest. Just unfortunate to hit the black swan so badly here, both the. Charts. Currency in USD 38. ASX - Day TradingA new thread to put trading comments / reasoning / opinions in. Yet since market announcement of Phase 2 completion, this. In 2005, IIH cost the American health care. Loading interactive chart. IXC Valuation Report MST. ASX - By Stock. , page-4. ASX - By Stock. ASX - Day TradingApril 20 (Reuters) - Invex Therapeutics Ltd (IXC) : MINISTRY OF HEALTH APPROVAL FOR IIH EVOLVE CLINICAL TRIAL IN ISRAELInvestor Presentation, page-2. If nothing has occurred with IXC for 2-3 days, we are happy to see no posts for 2-3 days, when there is excitement around a new development, then we can all get together to discuss and speculate. Latest Posts ForumsThis doesn't mean that IXC is doomed, just that things are more a gamble than an investment at the moment. Commodities. 5¢ INVEX THERAPEUTICS LTD - Discussion. Latest Posts. Market open. A promising development for IXC, a company with a current Phase III trial that is expected to finish dosing in 12 months time, We hear from a patient from the Phase II trial completed 2 years ago, with our current Phase III trial ongoing as we speak: Tony Grist - 5th largest holder in IXC Tom Henderson - 2nd largest holder in IXC Kim Hogan - 6th largest holder in IXC and now Simon Joyner - 14th largest holder in IXC Just a background of this board of advice. Market . ASX - Short Term Trading. At that time the total costs of IIH exceeded $444,000,000. 38 was the valuation MST gave IXC 9 months ago Considering we are now even further de-risked, getting to the end result, wonder what MST valuation would be now. Appendix 4E and Annual Report, page-3. 0¢ Sentiment: Buy Disclosure: Held Created with Sketch. Latest Posts. IXC “ presented “ about the AGM time to who ? If the company is aware ( as others seem to think) of an individual seller then they need to be proactive and take them out . ASX - By Stock. Hopefully that placement overhang will be removed today tomorrow and the share price will catch up. Latest Posts. . Australia's largest stock trading and investment forum Australia's #1 stock forumCreated with Sketch. Umbrella Society is a proud Living Wage Employer! Greater Victoria's official living wage has been adjusted to $25. ASX - Short Term Trading. @FullMoonFever Another chart request if you are up for it please thanks in advance, page-7. Hi guys, after discussion with Tom I have kind of mapped out the timeline to what is to be achieved. View listing photos, review sales history, and use our detailed real estate filters to find the perfect place. Charts. Initial FDA and EMA Advice on Presendin Development, page-3. no point selling now. sentiment based on opinions from HotCopper and others. . ASX - By Stock. , page-4. ASX - Day Trading. Forums. Forums. ASX - Day Trading. Target our investor community with our suite of Hotcopper Advertising opportunities. ASX - By Stock. Market . Last updated 10. Charts. Market . ASX - By Stock. Loading. . Re-purposed FDA drug for other illness with amazing effect as domenstrated in P2 results which ever drove sp to $2. A new thread to put trading comments / reasoning / opinions in. . Given the quality of the posters on the IXC thread I am confident others will do the same. ASX - By Stock. Get the edge as an investor: Subscribe to our daily newsletter for EXCLUSIVE insights into HotCopper!. ASX - Day TradingCreated with Sketch. 6% $DLM 50. More. , page-5. 0 Great analysis. ASX - Short Term Trading. ASX - General. Wouldn’t surprised me if they turn this company into something else if he keeps buyingCreated with Sketch. 1950. IXC has alot of catching up to do. Charts. Created with Sketch. Last edited by ejjwj: 28/06/23. ASX - By Stock. Thought that this would be worthy of its own thread, a great starting place for those new to IXC and arguably the best presentation to date, Worth a. pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. P3 will be kicked off in early CY2021. June 23 (Reuters) - Invex Therapeutics Ltd (IXC) : GRANTING OF ORPHAN DRUG DESIGNATION FOR EXENATIDE IN TREATMENT OF MODERATE TO SEVERE TRAUMATIC BRAIN. Folks say we are pioneers of craft ice cream in Victoria. ASX - General. ASX - General. . 10 Upvote. Quarterly Activities/Appendix 4C Cash Flow Report. 0¢ Sentiment: Buy Disclosure: Held. . . ASX - Day TradingAs thread states post your questions here and let’s start compiling a list. INVEX THERAPEUTICS LTD (ASX:IXC) - IXC chart, page-9 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum Forums ASX - By Stock IXC. Forums. ASX - By Stock. Join the HotCopper ASX share market forum today for free. Exciting times now that IXC is finally on the map!!! FYI considering charting is subjective that 1. , page-3. Latest Posts ForumsiShares Global Energy ETF (IXC) Add to watchlist NYSEArca - Nasdaq Real Time Price. 6 Upvote. 26 area could be wrong and it could go for example to $3. . ASX - General. 1950. , page-5. Created with Sketch. I think having this out we can discuss on the way. ASX - By Stock. 026. . ASX - By Stock. Cold Comfort Ice Cream Company, Victoria, British Columbia. Forums. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of. 38 Biotechnology stocks are valued based on a risk. HotCopper has news, discussion, prices and market data on IONIC RARE EARTHS LIMITED. Forums. , page-35. ASX - By Stock. pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. 76 (-1. Webinvest Pty Ltd<Olsb Unit A/C>. . 06KBNotification of cessation of securities - IXC. Management have earmarked this a significant milestone - given they previously tied it to performance. , page-20. Timeline Annotations of the IXC Chart Story Thus Far - IXC IPO'd in mid 2019 with Phase II data due Mid 2020, stock performs very well on IPO with tight T20 - The stock rose in anticipation for the Mid 2020 Phase II data read out in early 2020 - Before crashing alongside the Covid 19 Market Crash Hysteria in March 2020 AND all volume the last 18 months has led to a higher T20 ownership) meanwhile we have a mere 3 posts regarding an IXC job listing for a CMO that's description can be interpreted as hinting at a second indication. Created with Sketch. The Calmer Co (ASX:CCO) breaks new ground in Australian Retail with Kava shots to launch in Coles from January 2024Hi guys, after discussion with Tom I have kind of mapped out the timeline to what is to be achieved. . I don't mind a capital return but you have to think that a reverse take over of some sort can happen here and that IXC would have lots of choices. Market . Market . 3¢. Chairman's Address to Shareholders and PresentationHi guys, after discussion with Tom I have kind of mapped out the timeline to what is to be achieved. Update - Notification regarding unquoted securities - IXC. , page-4. 5¢ Sentiment: Buy Disclosure: Held Ive compared IXC to NEU before and believe we approx. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of. 5% last year. Forums. See page-34. . Market Cap $16. I bought the chart from base lows looking for a trade. IXC current EV is close to $0 so again Im not sure what OSL valuation is but I dont think it stacks up as good as IXC and where IXC is at in its timeline. Share I've got no issues with it. Australia's largest stock trading and investment forum Australia's #1 stock forumMay 18 (Reuters) - Invex Therapeutics Ltd (IXC) : INVEX THERAPEUTICS SEEKS TRADING HALT PENDING RELEASE ON RESULTS OF ITS PHASE II TRIAL & UNDERTAKING A. Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-3. Share Ok news not the greatest but I dont think its as bad as people gonna re-act (mainly retailers) Primary endpoint remains unchanged Protocol changes focus on reordering secondary endpoints - replacing PMD with the more. Invex Files Pre-IND/Type B Meeting Request with US FDA IXC is a long term play mate, not a daytraders plaything as too illiquid. Appendix 4E and Annual Report, page-2. Last updated 15. Of course, IXC’s BoD need to win back credibility for the market to more fairly value IXC’s TBI ODD… Having gone through the roller-coaster over the past one week, with my emotions now settled – I will be (slowly) buying-up in. Latest Posts. Market . ASX - By Stock. Interexchange Carrier, also known as IXC, is a telco that mainly provides long-distance communication services. Forums. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical developmentNotice of Annual General Meeting/Proxy Form. Forums.